Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development

Summary

Company, the leading business intelligence provider, has released its latest research, “Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development”, which provides insights into the global oncology therapeutics market and market forecasts until 2017. The report provides an in-depth analysis of major oncology indications, which includes breast cancer, colorectal cancer, Non-Hodgkin’s lymphoma (NHL), Non-Small Cell Lung Cancer (NSCLC), prostate cancer, ovarian cancer, cervical cancer and head and neck cancer. The report also includes insights into the oncology therapeutics R&D pipeline. It analyzes the competitive landscape in the oncology therapeutics market through analysis of M&A, licensing and co-development deals. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Company’s team of industry experts.

Company finds that the global oncology therapeutics market was valued at $33.3 billion in 2010, increasing from $12.8 billion in 2002 to $33.3 billion at a CAGR of 12.7% during the review period 2002–2010. The market is projected to witness moderate growth of 5.7% during the forecast period 2010–2017 to reach $48.9 billion in 2017. The moderate growth of the market can be attributed to patent expiries for major drugs, including Taxotere (docetaxel) and Eloxatin (oxaliplatin), and the presence of strong targeted therapies in many therapeutic indications including breast cancer, colorectal cancer and NHL. The other major indications that have the presence of targeted therapeutics are expected to witness increased competition due to the launch of new targeted therapeutics during the forecast period. The pipeline for the oncology therapeutics market is strong and is expected produce targeted drugs with better safety and efficacy profiles. Competitive activity is high in the oncology therapeutics market and is expected to increase due to the need for new therapeutics to meet the unmet needs of late-stage cancer patients.

Scope

- Data and analysis on the global oncology therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the oncology therapeutics market from 2002-2010 with forecasts to 2017.
- Market data on the therapeutic landscape which covers breast cancer, colorectal cancer, NHL, NSCLC, prostate cancer, ovarian cancer, cervical cancer and head and neck cancer. This includes market size, market share, annual cost of therapy, treatment flow algorithm and branded and generic share.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the global oncology therapeutics market which includes companies such as Roche, Sanofi, AstraZeneca, Eli Lilly, and Novartis.
- Key M&A activities and licensing and co-development agreements that took place from 2007-2011 in the global oncology therapeutics market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and oncology therapeutics market segments poised for strong growth.
- Create a more tailored country strategy through the understanding of key drivers and barriers of the global oncology therapeutics market.
- Develop key strategic initiatives by understanding the key focus areas and top selling therapeutics of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

1.1 List of Tables 7
1.2 List of Figures 11
2 Oncology Therapeutics Market to 2017 - Introduction 14
2.1 Company Report Guidance 15
3 Oncology Therapeutics Market to 2017 - Market Overview 16
3.1 Revenue Forecasts for Oncology Therapeutics Market 16
3.1.1 Revenue 16
3.1.2 Annual Cost of Treatment 22
3.2 Treatment Usage Patterns 23
3.3 Drivers and Barriers for Oncology Therapeutics Market 25
3.3.1 Drivers 25
3.3.2 Barriers 26
4 Oncology Therapeutics Market to 2017 - Geographical Landscape 28
4.1 The US 28
4.1.1 Revenue 28
4.1.2 Annual Cost of Treatment 29
4.1.3 Treatment Usage Patterns 30
4.2 Top Five Countries of Europe 32
4.2.1 Revenue 32
4.2.2 Annual Cost of Treatment 33
4.2.3 Treatment Usage Patterns 34
4.3 Japan 36
4.3.1 Revenue 36
4.3.2 Annual Cost of Treatment 37
4.3.3 Treatment Usage Patterns 38
5 Oncology Therapeutics Market to 2017 - Therapeutic Landscape 40
5.1 Breast Cancer 40
5.1.1 Introduction 40
5.1.2 Survival Rates by Stage 42
5.1.3 Symptoms 42
5.1.4 Treatment Flow 43
5.1.5 Revenue 46
5.1.6 Annual Cost of Treatment 50
5.1.7 Treatment Usage Patterns 51
5.1.8 Drivers and Barriers for Breast Cancer Therapeutics Market 53
5.2 Colorectal Cancer 55
5.2.1 Introduction 55
5.2.2 Survival Rates by Stage 56
5.2.3 Symptoms 56
5.2.4 Treatment Flow 57
5.2.5 Revenue 60
5.2.6 Treatment Usage Patterns 65
5.2.7 Drivers and Barriers for Colorectal Cancer Therapeutics Market 67
5.3 Non-Hodgkin’s Lymphoma Therapeutics Market 68
5.3.1 Introduction 68
5.3.2 Survival Rates by Stage 69
5.3.3 Symptoms 70
5.3.4 Treatment Flow 70
5.3.5 Revenue 71
5.3.6 Annual Cost of Treatment 75
5.3.7 Treatment Usage Patterns 76
5.3.8 Drivers and Barriers for Non-Hodgkin’s Lymphoma Market 77
5.4 Non-Small Cell Lung Cancer (NSCLC) 78
5.4.1 Introduction 78
5.4.2 Survival Rates by Stage 79
5.4.3 Symptoms 79
5.4.4 Treatment Flow 80
5.4.5 Revenue 82
5.4.6 Treatment Usage Patterns 87
5.4.7 Drivers and Barriers for NSCLC Therapeutics Market 88
5.5 Prostate Cancer Therapeutics Market 89
5.5.1 Introduction 89
5.5.2 Survival Rates 90
5.5.3 Symptoms 90
5.5.4 Treatment Flow 90
5.5.5 Revenue 92
5.5.6 Treatment Usage Patterns 96
5.5.7 Drivers and Barriers 97
5.6 Ovarian Cancer 99
5.6.1 Introduction 99
5.6.2 Survival Rates 99
5.6.3 Symptoms 100
5.6.4 Treatment Flow 100
5.6.5 Revenue 101
5.6.6 Treatment Usage Patterns 106
5.6.7 Drivers and Barriers 107
5.7 Cervical Cancer 108
5.7.1 Introduction 108
5.7.2 Survival Rates 109
5.7.3 Symptoms 110
5.7.4 Treatment Flow 110
5.7.5 Revenue 111
5.7.6 Treatment Usage Patterns 116
5.7.7 Drivers and Barriers 118
5.8 Head and Neck Cancer 119
5.8.1 Introduction 119
5.8.2 Survival Rates 120
5.8.3 Symptoms 120
5.8.4 Treatment Flow 121
5.8.5 Revenue 122
5.8.6 Treatment Usage Patterns 127
5.8.7 Drivers and Barriers 129
6 Oncology Therapeutics Market to 2017 - Product Pipeline Analysis 130
6.1 Introduction 130
6.2 R&D Pipeline - Breast Cancer 132
6.2.1 Promising Drugs in the Pipeline 141
6.3 R&D Pipeline - Colorectal Cancer 142
6.3.1 Promising Molecules in the Pipeline 150
6.4 R&D Pipeline - NHL 151
6.4.1 Non-Hodgkin’s Lymphoma Therapeutics Pipeline 151
6.4.2 Promising Pipeline Molecules 156
6.5 R&D Pipeline - NSCLC 157
6.5.1 Promising Pipeline Molecules 163
6.6 R&D Pipeline - Prostate Cancer 164
6.6.1 Promising Pipeline Molecules 170
6.7 R&D Pipeline - Ovarian Cancer 171
6.7.1 Promising Pipeline Molecules 178
6.8 R&D Pipeline - Cervical Cancer 179
6.8.1 Promising Pipeline Molecules 181
6.9 R&D Pipeline - Head and Neck Cancer 181
6.9.1 Promising Pipeline Products 184
6.9.2 Pipeline Analysis 185
7 Oncology Therapeutics Market to 2017 - Competitive Landscape 186
7.1 Market Share Analysis 186
7.2 Competitive Profiling 187
7.2.1 F. Hoffmann-La Roche 187
7.2.2 AstraZeneca PLC 188
7.2.3 Eli Lilly and Company 190
7.2.4 Sanofi 191
7.2.5 Novartis AG 192
8 Oncology Therapeutics Market to 2017 - Strategic Consolidations 193
8.1 M&A Landscape 193
8.1.1 M&A Deals by Year 195
8.1.2 M&A Deals by Geography 196
8.1.3 M&A Deals by Value 197
8.1.4 M&A Deals by Deal Type 198
8.2 R&D Licensing Agreements 199
8.2.1 Deals by Year 200
8.2.2 Deals by Geography 201
8.2.3 Deals by Value 202
8.3 Co-Development Agreements 203
8.3.1 Deals by Year 204
8.3.2 Deals by Geography 205
8.3.3 Deals by Value 206
9 Appendix 207
9.1 Market Definitions 207
9.2 Abbreviations 207
9.3 Research Methodology 209
9.3.1 Coverage 209
9.3.2 Secondary Research 210
9.3.3 Primary Research 210
9.4 Therapeutic Landscape 211
9.4.2 Market Size by Geography 213
9.5 Geographical Landscape 214
9.6 Pipeline Analysis 214
9.7 Competitive Landscape 214
9.7.1 Expert Panel Validation 214
9.8 Contact Us 214
9.9 Disclaimer 214
9.10 Sources 215

1.1 List of Tables

Table 1: Oncology Therapeutics Market to 2017, Global, Revenue, ($m), 2002-2010 16
Table 2: Oncology Therapeutics Market to 2017, Global, Revenue Forecasts, ($m), 2010-2017 16
Table 3: Oncology Therapeutics Market to 2017, Global, Revenue Share by Geography, ($m), 2002-2010 19
Table 4: Oncology Therapeutics Market to 2017, Global, Revenue Share by Geography, ($m), 2010-2017 19
Table 5: Oncology Therapeutics Market to 2017, Global, Annual Cost of Treatment, ($), 2002-2010 22
Table 6: Oncology Therapeutics Market to 2017, Global, Annual Cost of Treatment, ($), 2010-2017 22
Table 7: Oncology Therapeutics Market to 2017, Global, Treatment Usage Patterns, (‘000), 2002-2010 24
Table 8: Oncology Therapeutics Market to 2017, Global, Treatment Usage Patterns, (‘000), 2010-2017 24
Table 9: Oncology Therapeutics Market to 2017, The US, Revenue, ($m), 2002-2010 28
Table 10: Oncology Therapeutics Market to 2017, The US, Revenue Forecasts, ($m), 2010-2017 28
Table 11: Oncology Therapeutics Market to 2017, The US, Annual Cost of Treatment, ($), 2002-2010 29
Table 12: Oncology Therapeutics Market to 2017, The US, Annual Cost of Treatment, ($), 2010-2017 29
Table 13: Oncology Therapeutics Market to 2017, The US, Treatment Usage Patterns, (‘000), 2002-2010 30
Table 14: Oncology Therapeutics Market to 2017, The US, Treatment Usage Patterns, (‘000), 2010-2017 31
Table 15: Oncology Therapeutics Market to 2017, Top Five Countries in Europe, Revenue, ($m), 2002-2010 32
Table 16: Oncology Therapeutics Market to 2017, Top Five Countries in Europe, Revenue Forecasts, ($m), 2010-2017 32
Table 17: Oncology Therapeutics Market to 2017, Top Five Countries in Europe, Annual Cost of Treatment, ($), 2002-2010 33
Table 18: Oncology Therapeutics Market to 2017, Top Five Countries in Europe, Annual Cost of Treatment, ($), 2010-2017 33
Table 19: Oncology Therapeutics Market to 2017, Top Five Countries in Europe, Treatment Usage Patterns, (‘000), 2002-2010 34
Table 20: Oncology Therapeutics Market to 2017, Top Five Countries in Europe, Treatment Usage Patterns, (‘000), 2010-2017 35
Table 21: Oncology Therapeutics Market to 2017, Japan, Revenue, ($m), 2002-2010 36
Table 22: Oncology Therapeutics Market to 2017, Japan, Revenue Forecasts, ($m), 2010-2017 36
Table 23: Oncology Therapeutics Market to 2017, Japan, Annual Cost of Treatment, ($), 2002-2010 37
Table 24: Oncology Therapeutics Market to 2017, Japan, Annual Cost of Treatment, ($), 2010-2017 37
Table 25: Oncology Therapeutics Market to 2017, Japan, Treatment Usage Patterns, (‘000), 2002-2010 38
Table 26: Oncology Therapeutics Market to 2017, Japan, Treatment Usage Patterns, (‘000), 2010-2017 39
Table 27: Breast Cancer Therapeutics Market, Global, Cancer Categorized by Disease Stage, 2011 40
Table 28: Breast Cancer Therapeutics Market, Global, Stage, Distribution and Survival For Breast Cancer Patients in the US, (%), 2001-2007 42
Table 29: Breast Cancer Therapeutics Market, Global, Revenue ($m), 2002-2010 46
Table 30: Breast Cancer Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 46
Table 31: Breast Cancer Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2010 47
Table 32: Breast Cancer Therapeutics Market, Global, Geographical Segmentation ($m), 2010-2017 48
Table 33: Breast Cancer Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 50
Table 34: Breast Cancer Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 50
Table 35: Breast Cancer Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2002-2010 51
Table 36: Breast Cancer Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2010-2017 52
Table 37: Colorectal Cancer Therapeutics Market, Global, Cancer Categorized by Disease Stage 56
Table 38: Colorectal Cancer, Stage Distribution and 5-year Relative Survival by Stage at Diagnosis for Patients in the US, (%), 2001-2007 56
Table 39: Colorectal Cancer Therapeutics Market, Global, Revenue ($m), 2002-2010 60
Table 40: Colorectal Cancer Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 60
Table 41: Colorectal Cancer Therapeutics Market, Global, Geographic Segmentation ($m), 2002-2010 62
Table 42: Colorectal Cancer Therapeutics Market, Global, Geographic Segmentation ($m), 2010-2017 62
Table 43: Colorectal Cancer Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 64
Table 44: Colorectal Cancer Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 64
Table 45: Colorectal Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2010 65
Table 46: Colorectal Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2010-2017 66
Table 47: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, NHL Categorized by Disease Stage 68
Table 48: NHL Therapeutics Market, Global, Stage Distribution and 5-Year Survival Rates by Stage at Diagnosis for Patients in the US, (%), 2001-2007 69
Table 49: NHL Therapeutics Market, Global, Revenue ($m), 2002-2010 71
Table 50: NHL Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 72
Table 51: NHL Therapeutics Market, Global, Geographic Segmentation ($m), 2002-2010 73
Table 52: NHL Therapeutics Market, Global, Geographic Segmentation ($m), 2010-2017 74
Table 53: NHL Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 75
Table 54: NHL Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 75
Table 55: NHL Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2010 76
Table 56: NHL Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2010-2017 76
Table 57: NSCLC Therapeutics Market, Global, Cancer Categorized by Disease Stage 78
Table 58: NSCLC Therapeutics Market, Global, Stage Distribution and Survival For Lung Cancer Patients in the US, (%), 2000-2007 79
Table 59: NSCLC Therapeutics Market, Global, Revenue ($m), 2002-2010 82
Table 60: NSCLC Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 82
Table 61: NSCLC Therapeutics Market, Geographical Segmentation, ($m), 2002-2010 84
Table 62: NSCLC Therapeutics Market, Geographical Segmentation, ($m), 2010-2017 84
Table 63: NSCLC Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 86
Table 64: NSCLC Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 86
Table 65: NSCLC Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2010 87
Table 66: NSCLC Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2010-2017 87
Table 67: Prostate Cancer Therapeutics Market, Global, Cancer Characterized by Disease Stage 89
Table 68: Prostate Cancer Therapeutics Market, Global, Stage Distribution and Survival For Prostate Cancer Patients in the US, (%), 2000-2007 90
Table 69: Prostate Cancer Therapeutics Market, Global, Revenue ($m), 2002-2010 92
Table 70: Prostate Cancer Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 92
Table 71: Prostate Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 93
Table 72: Prostate Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 94
Table 73: Prostate Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2010 95
Table 74: Prostate Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2010 95
Table 75: Prostate Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2010 96
Table 76: Prostate Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2010-2017 97
Table 77: Ovarian Cancer Therapeutics Market, Global, Surgical Staging of Ovarian Cancer, 2011 99
Table 78: Ovarian Cancer Therapeutics Market, Global, Stage Distribution and Survival For Ovarian Cancer Patients in the US, (%), 2001-2007 99
Table 79: Ovarian Cancer Therapeutics Market, Global, Post-Operative Treatment of Ovarian Cancer, 2011 100
Table 80: Ovarian Cancer Therapeutics Market, Global, Revenue, ($m), 2002-2010 101
Table 81: Ovarian Cancer Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 101
Table 82: Ovarian Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 103
Table 83: Ovarian Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 103
Table 84: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2010 105
Table 85: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2010-2017 105
Table 86: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Pattern, (‘000s), 2002-2010 106
Table 87: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Pattern, (‘000s), 2010-2017 107
Table 88: Ovarian Cancer Therapeutics Market, Clinical Staging of Ovarian Cancer, 2011 109
Table 89: Cervical Cancer Therapeutics Market, Global, Stage Distribution and Survival For Cervical Cancer Patients in the US, (%), 2001-2007 109
Table 90: Cervical Cancer Therapeutics Market, Global, Treatment Flow for Cervical Cancer, 2011 110
Table 91: Cervical Cancer Therapeutics Market, Global, Revenue, ($m), 2002-2010 111
Table 92: Cervical Cancer Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 111
Table 93: Cervical Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 113
Table 94: Cervical Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 113
Table 95: Cervical Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2010 115
Table 96: Cervical Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2010-2017 115
Table 97: Cervical Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2010 116
Table 98: Cervical Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2017 117
Table 99: Head and Neck Cancer Therapeutics Market, Global, Staging for Head and Neck Cancer, 2011 119
Table 100:Head and Neck Cancer Therapeutics Market, Global, Stage Distribution and Survival For Head and Neck Cancer Patients in the US, (%), 1998-2001 120
Table 101:Head and Neck Cancer Therapeutics Market, Global, Revenue, ($m), 2002-2010 122
Table 102:Head and Neck Cancer Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 122
Table 103:Head and Neck Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 124
Table 104:Head and Neck Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 124
Table 105:Head and Neck Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2010 126
Table 106:Head and Neck Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2010-2017 126
Table 107:Head and Neck Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2010 127
Table 108:Head and Neck Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2010-2017 128
Table 109:Breast Cancer Therapeutics Market, Global, Pipeline, Filed Molecules, 2011 132
Table 110:Breast Cancer Therapeutics Market, Pipeline, Global, Phase III Molecules, 2011 133
Table 111:Breast Cancer Therapeutics Market, Pipeline, Global, Phase II Molecules, 2011 134
Table 112:Breast Cancer Therapeutics Market, Pipeline, Global, Phase I Molecules, 2011 138
Table 113:Breast Cancer Therapeutics Market, Pipeline, Global, Pre-Clinical Stage Molecules, 2011 140
Table 114:Breast Cancer Therapeutics Market, Pipeline, Global, Discovery Stage Molecules, 2011 141
Table 115:Colorectal Cancer Therapeutics Market, Global, Product Pipeline, Phase III, 2011 143
Table 116:Colorectal Cancer Therapeutics Market, Product Pipeline, Global, Phase II, 2011 144
Table 117:Colorectal Cancer Therapeutics Market, Global, Product Pipeline, Phase I, 2011 147
Table 118:Colorectal Cancer Therapeutics Market, Global, Product Pipeline, Pre-Clinical Stage, 2011 149
Table 119:Colorectal Cancer Therapeutics Market, Global, Product Pipeline, Discovery Stage, 2011 149
Table 120:NHL Therapeutics Market, Global, Product Pipeline, NDA Filed, 2011 151
Table 121:NHL Therapeutics Market, Global, Product Pipeline, Phase III, 2011 152
Table 122:NHL Therapeutics Market, Global, Product Pipeline, Phase II, 2011 153
Table 123:NHL Therapeutics Market, Global, Product Pipeline, Phase I, 2011 154
Table 124:NHL Therapeutics Market, Global, Product Pipeline, Pre-Clinical Stage, 2011 155
Table 125:NHL Therapeutics Market, Global, Product Pipeline, Discovery Stage, 2011 156
Table 126:NSCLC Therapeutics Market, Global, Product Pipeline, Filed Molecules, 2011 157
Table 127:NSCLC Therapeutics Market, Global, Product Pipeline, Phase III, 2011 158
Table 128:NSCLC Therapeutics Market, Product Pipeline, Global, Phase II, 2011 159
Table 129:NSCLC Therapeutics Market, Product Pipeline, Global, Phase I, 2011 161
Table 130:NSCLC Therapeutics Market, Product Pipeline, Global, Pre-Clinical Stage, 2011 162
Table 131:NSCLC Therapeutics Market, Product Pipeline, Global, Discovery Stage, 2011 163
Table 132:Prostate Cancer Therapeutics Market, Global, Product Pipeline, Filed Molecules, 2011 164
Table 133:Prostate Cancer Therapeutics Market, Global, Product Pipeline, Phase III, 2011 165
Table 134:Prostate Cancer Therapeutics Market, Product Pipeline, Phase II, 2011 166
Table 135:Prostate Cancer Therapeutics Market, Global, Product Pipeline, Phase I, 2011 168
Table 136:Prostate Cancer Therapeutics Market, Global, Product Pipeline, Pre-Clinical Stage, 2011 169
Table 137:Prostate Cancer Therapeutics Market, Global, Product Pipeline, Discovery Stage, 2011 170
Table 138:Ovarian Cancer Therapeutics Market, Global, Product Pipeline, Filed, 2011 171
Table 139:Ovarian Cancer Therapeutics Market, Global, Product Pipeline, Phase III, 2011 172
Table 140:Ovarian Cancer Therapeutics Market, Global, Product Pipeline, Phase II, 2011 173
Table 141:Ovarian Cancer Therapeutics Market, Global, Product Pipeline, Phase I, 2011 175
Table 142:Ovarian Cancer Therapeutics Market, Global, Product Pipeline, Pre-Clinical Stage, 2011 176
Table 143:Ovarian Cancer Therapeutics Market, Global, Product Pipeline, Discovery Stage, 2011 177
Table 144:Cervical Cancer Therapeutics Market, Global, Product Pipeline, Phase III, 2011 179
Table 145:Cervical Cancer Therapeutics Market, Global, Product Pipeline, Phase II, 2011 180
Table 146:Cervical Cancer Therapeutics Market, Global, Product Pipeline, Phase I, 2011 180
Table 147:Cervical Cancer Therapeutics Market, Global, Product Pipeline, Pre-Clinical Stage, 2011 180
Table 148:Head and Neck Cancer Therapeutics Market, Global, Product Pipeline, Phase III, 2011 182
Table 149:Head and Neck Cancer Therapeutics Market, Global, Product Pipeline, Phase II, 2011 182
Table 150:Head and Neck Cancer Therapeutics Market, Global, Product Pipeline, Phase I, 2011 183
Table 151:Head and Neck Cancer Therapeutics Market, Global, Product Pipeline, Pre-Clinical Stage, 2011 184
Table 152:Head and Neck Cancer Therapeutics Market, Global, Product Pipeline, Discovery Stage, 2011 184
Table 153:Oncology Therapeutics Market, Global, Major M&A Deals, 2007–2011 193
Table 154: Oncology Therapeutics Market, Global, M&A Deals by Year, 2007–2011 195
Table 155: Oncology Therapeutics Market, Global, M&A Deals by Geography, 2007–2011 196
Table 156: Oncology Therapeutics Market, Global, M&A Deals by Value, 2007–2011 197
Table 157: Oncology Therapeutics Market, Global, M&A Deals by Deal Type, 2007–2011 198
Table 158:Oncology Therapeutics Market, Global, Major R&D Licensing Deals, 2007-2011 199
Table 159:Oncology Therapeutics Market, Global, R&D Licensing Deals by Year, 2007-2011 200
Table 160:Oncology Therapeutics Market, Global, R&D Licensing Deals by Geography, 2007-2011 201
Table 161:Oncology Therapeutics Market, Global, R&D Licensing Deals by Value, (%), 2007-2011 202
Table 162:Oncology Therapeutics Market, Global, Co-Development Deals by Year, 2007-2011 203
Table 163:Oncology Therapeutics Market, Global, Co-Development Deals by Year, 2007-2011 204
Table 164:Oncology Therapeutics Market, Global, Co-Development Deals by Geography, (%), 2007-2011 205
Table 165:Oncology Therapeutics Market, Global, Co-Development Deals by Value, 2007-2011 206

1.2 List of Figures

Figure 1: Oncology Therapeutics Market to 2017, Global, Revenue Forecasts, ($m), 2002–2017 16
Figure 2: Oncology Therapeutics Market to 2017, Opportunity Analysis, 2002-2017 17
Figure 3: Oncology Therapeutics Market to 2017, Global, Revenue Share by Geography, ($m), 2002-2017 18
Figure 4: Oncology Therapeutics Market to 2017, Global, Brand and Generic Share (%), 2010-2017 20
Figure 5: Oncology Therapeutics Market to 2017, Global, Annual Cost of Treatment, ($), 2002-2017 22
Figure 6: Oncology Therapeutics Market to 2017, Global, Treatment Usage Patterns, (‘000), 2002-2017 23
Figure 7: Oncology Therapeutics Market to 2017, Global, Drivers and Barriers, 2011 25
Figure 8: Oncology Therapeutics Market to 2017, The US, Revenue Forecasts, ($m), 2002-2017 28
Figure 9: Oncology Therapeutics Market to 2017, The US, Annual Cost of Treatment, ($), 2002-2017 29
Figure 10: Oncology Therapeutics Market to 2017, The US, Treatment Usage Patterns, (‘000), 2002-2017 30
Figure 11: Oncology Therapeutics Market to 2017, Top Five Countries in Europe, Revenue Forecasts, ($m), 2002-2017 32
Figure 12: Oncology Therapeutics Market to 2017, Top Five Countries in Europe, Annual Cost of Treatment, ($), 2002-2017 33
Figure 13: Oncology Therapeutics Market to 2017, Top Five Countries in Europe, Treatment Usage Patterns, (‘000), 2002-2017 34
Figure 14: Oncology Therapeutics Market to 2017, Japan, Revenue Forecasts, ($m), 2002-2017 36
Figure 15: Oncology Therapeutics Market to 2017, Japan, Annual Cost of Treatment, ($), 2002-2017 37
Figure 16: Oncology Therapeutics Market to 2017, Japan, Treatment Usage Patterns, (‘000), 2002-2017 38
Figure 17: Breast Cancer Therapeutics Market, Global, Types of Breast Cancer, 2011 41
Figure 18: Breast Cancer Therapeutics Market, Global, Treatment Flow Algorithm, Stage 0, 2011 43
Figure 19: Breast Cancer Therapeutics Market, Global, Treatment Flow Algorithm, Stage I and II, 2011 43
Figure 20: Breast Cancer Therapeutics Market, Global, Treatment Flow Algorithm, Stage III, 2011 44
Figure 21: Breast Cancer Therapeutics Market, Global, Treatment Flow Algorithm, Stage IV, 2011 44
Figure 22: Breast Cancer Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 46
Figure 23: Breast Cancer Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017 47
Figure 24: Breast Cancer Therapeutics Market, Global, Brand and Generic Share by Revenue (%), 2010-2017 49
Figure 25: Breast Cancer Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 50
Figure 26: Breast Cancer Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2002-2017 51
Figure 27: Breast Cancer Therapeutics Market, Global, Drivers and Barriers, 2011 53
Figure 28: Colorectal Cancer Therapeutics Market, Global, Treatment Flow Algorithm for Colon Cancer, 2011, Part-1 57
Figure 29: Colorectal Cancer Therapeutics Market, Global, Treatment Flow Algorithm for Colon Cancer, 2011, Part-2 58
Figure 30: Colorectal Cancer Therapeutics Market, Global, Treatment Flow Algorithm for Rectal Cancer, 2011 59
Figure 31: Colorectal Cancer Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 60
Figure 32: Colorectal Cancer Therapeutics Market, Global, Geographic Segmentation ($m), 2002-2017 61
Figure 33: Colorectal Cancer Therapeutics Market, Global, Brand and Generic Drug Share by Revenue (%), 2010-2017 63
Figure 34: Colorectal Cancer Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 64
Figure 35: Colorectal Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2017 65
Figure 36: Colorectal Cancer Therapeutics Market, Global, Drivers and Barriers, 2011 67
Figure 37: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Non Hodgkin Lymphoma Classification, 2011 69
Figure 38: NHL Therapeutics Market, Global, Treatment Flow Algorithm, 2011 70
Figure 39: NHL Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 71
Figure 40: NHL Therapeutics Market, Global, Geographic Segmentation ($m), 2002-2017 73
Figure 41: NHL Therapeutics Market, Global, Branded and Generic Drug Share by Revenue (%), 2010-2017 74
Figure 42: NHL Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 75
Figure 43: NHL Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2017 76
Figure 44: NHL Therapeutics Market, Global, Drivers and Barriers, 2011 77
Figure 45: NSCLC Therapeutics Market, Global, Treatment Flow Algorithm, 2011, Part 1 80
Figure 46: NSCLC Therapeutics Market, Global, Treatment Flow Algorithm, 2011, Part 2 81
Figure 47: NSCLC Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 82
Figure 48: NSCLC Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 83
Figure 49: NSCLC Therapeutics Market, Global, Brand and Generic Drug Share by Revenue (%), 2010-2017 85
Figure 50: NSCLC Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 86
Figure 51: NSCLC Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2017 87
Figure 52: NSCLC Therapeutics Market, Global, Drivers and Barriers, 2011 88
Figure 53: Prostate Cancer Therapeutics Market, Global, Treatment Flow Algorithm, 2011 90
Figure 54: Prostate Cancer Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 92
Figure 55: Prostate Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 93
Figure 56: Prostate Cancer Therapeutics Market, Global, Branded and Generic Drug Share by Revenue (%), 2010-2017 94
Figure 57: Prostate Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2017 95
Figure 58: Prostate Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2017 96
Figure 59: Prostate Cancer Therapeutics Market, Global, Drivers and Barriers, 2011 97
Figure 60: Ovarian Cancer Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 101
Figure 61: Ovarian Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 102
Figure 62: Ovarian Cancer Therapeutics Market, Global, Branded and Generic Drug Share by Revenue (%), 2010-2017 104
Figure 63: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2017 105
Figure 64: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Pattern, (‘000s), 2002-2017 106
Figure 65: Ovarian Cancer Therapeutics Market, Global, Drivers and Barriers, 2011 107
Figure 66: Cervical Cancer Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 111
Figure 67: Cervical Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 112
Figure 68: Cervical Cancer Therapeutics Market, Global, Global, Brand and Generic Share by Revenue (%), 2010-2017 114
Figure 69: Cervical Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2017 115
Figure 70: Cervical Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2017 116
Figure 71: Cervical Cancer Therapeutics Market, Global, Drivers and Barriers, 2011 118
Figure 72: Head and Neck Cancer Therapeutics Market, Global, Treatment Flow Algorithm, 2011 121
Figure 73: Head and Neck Cancer Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 122
Figure 74: Head and Neck Cancer Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 123
Figure 75: Head and Neck Cancer Therapeutics Market, Global, Branded and Generic Drug Share by Revenue (%), 2010-2017 125
Figure 76: Head and Neck Cancer Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2017 126
Figure 77: Head and Neck Cancer Therapeutics Market, Global, Treatment Usage Pattern (‘000), 2002-2017 127
Figure 78: Head and Neck Cancer Therapeutics Market, Global, Drivers and Barriers, 2011 129
Figure 79: Oncology Therapeutics Market, Global Product Pipeline by Clinical Trial Phase (%), 2011 130
Figure 80: Oncology Therapeutics Market, Global Product Pipeline by Indication (%), 2011 131
Figure 81: Breast Cancer Therapeutics, Global, Pipeline Analysis, (%), 2011 132
Figure 82: Colorectal Cancer, Product Pipeline by Phase, Global, (%), 2011 142
Figure 83: NHL Therapeutics Market, Global, Product Pipeline by Phase, Global, (%), 2011 151
Figure 84: NSCLC Therapeutics Market, Global, Product Pipeline by Phase, (%), 2011 157
Figure 85: Prostate Cancer Therapeutics Market, Global, Product Pipeline by Phase, (%), 2011 164
Figure 86: Ovarian Cancer Therapeutics Market, Global, Product Pipeline by Phase, (%), 2011 171
Figure 87: Cervical Cancer Therapeutics Market, Global, Product Pipeline by Phase, (%), 2011 179
Figure 88: Head and Neck Cancer Therapeutics Market, Global, Product Pipeline by Phase, (%), 2011 181
Figure 89: Oncology Therapeutics Market, Global, Market Share Analysis, (%), Based on 2010 Sales 186
Figure 90: Oncology Therapeutics Market, Roche, Company Overview, 2011 187
Figure 91: Oncology Therapeutics Market, Roche, SWOT, 2011 188
Figure 92: Oncology Therapeutics Market, AstraZeneca, Company Overview, 2011 188
Figure 93: Oncology Therapeutics Market, AstraZeneca, SWOT, 2011 189
Figure 94: Oncology Therapeutics Market, Eli Lilly and Company, Company Overview, 2011 190
Figure 95: Oncology Therapeutics Market, Eli Lilly and Company, SWOT, 2011 190
Figure 96: Oncology Therapeutics Market, Sanofi, Company Overview, 2011 191
Figure 97: Oncology Therapeutics Market, Sanofi, SWOT, 2011 191
Figure 98: Oncology Therapeutics Market, Novartis AG, Company Overview, 2011 192
Figure 99:Oncology Therapeutics Market, Novartis, SWOT, 2011 192
Figure 100: Oncology Therapeutics Market, Global, M&A Deals by Year, 2007–2011 195
Figure 101:Oncology Therapeutics Market, Global, M&A Deals by Geography, (%), 2007–2011 196
Figure 102: Oncology Therapeutics Market, Global, M&A Deals by Value, (%), 2007–2011 197
Figure 103:Oncology Therapeutics Market, Global, M&A Deals by Deal Type, (%), 2007–2011 198
Figure 104:Oncology Therapeutics Market, Global, R&D Licensing Deals by Year, 2007-2011 200
Figure 105:Oncology Therapeutics Market, Global, R&D Licensing Deals by Geography, (%), 2007-2011 201
Figure 106:Oncology Therapeutics Market, Global, R&D Licensing Deals by Value, (%), 2007-2011 202
Figure 107:Oncology Therapeutics Market, Global, Co-Development Deals by Year, 2007-2011 204
Figure 108:Oncology Therapeutics Market, Global, Co-Development Deals by Geography, (%), 2007-2011 205
Figure 109:Oncology Therapeutics Market, Global, Co-Development Deals by Value, (%), 2007-2011 206
Figure 110:Company Market Forecasting Model 213

Companies Mentioned

F. Hoffmann-La Roche
AstraZeneca PLC
Eli Lilly and Company
Sanofi
Novartis AG